Major depressive disorder (MDD) remains one of the leading causes of disability worldwide, with many patients failing to achieve adequate symptom control despite multiple available antidepressants. Positive topline results from Definium Therapeutics' Phase 3 …

Recently, the FDA has requested Sarepta Therapeutics, Inc., a Massachusetts-based biopharmaceutical company, to suspend all distribution of its DMD gene therapy Elevidys (delandistrogene moxeparvovec), following the deaths of three patients—two non‑ambulatory teenagers and one …

Introduction If you asked us (and many other industrial consultants) what one of the most common commercial strategy mistakes we see in otherwise well-positioned early-stage companies is, without a doubt, it would be the …

Drug development is a complex and resource-intensive process that involves significant investments in research, clinical trials, and regulatory activities. As pharmaceutical companies evaluate the potential of assets, they employ various financial metrics. Two commonly …

Clinical research success rates of different disease areas have far-reaching implications in the structure of corporate R&D budgets, pharmaceutical asset valuation and, eventually, M&A activity. The report published in February 2021 considers success rates of clinical …